{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T11:04:42Z","timestamp":1789470282115,"version":"build-2803163510"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Pancreatic ductal adenocarcinoma (PDAC) remains a highly lethal malignancy requiring precise prognostic stratification. Although extrapancreatic extension (EPE) was removed from the American Joint Committee on Cancer 8th edition staging system in favor of size-based classification, emerging evidence suggests EPE retains prognostic relevance. This population-based study analyzed 22,045 patients with surgically resected PDAC from the Surveillance, Epidemiology, and End Results database (2004\u20132022) to evaluate EPE\u2019s prognostic significance and its interaction with tumor size. EPE was present in 78.0% of patients and independently predicted worse disease-specific survival (adjusted hazard ratio, 1.29; 95% confidence interval, 1.23\u20131.35). Notably, the prognostic impact of EPE varied nonlinearly with tumor size, exerting a stronger effect on smaller tumors. A modest but significant negative multiplicative interaction was identified (adjusted hazard ratio, 0.88; 95% confidence interval, 0.79\u20130.98), suggesting that patients with small EPE-positive tumors exhibited survival comparable to those with larger EPE-negative tumors. These findings were consistent across competing risk analyses. This study demonstrates that EPE remains an important prognostic factor in PDAC, with its effect modulated by tumor size. These results suggest that EPE assessment may warrant consideration in future postoperative staging and risk-stratification frameworks.<\/jats:p>","DOI":"10.1038\/s41598-026-60797-z","type":"journal-article","created":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T10:16:46Z","timestamp":1789467406000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Extrapancreatic extension exhibits tumor size-dependent prognostic impact in pancreatic cancer"],"prefix":"10.1038","volume":"16","author":[{"given":"Jun","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolin","family":"Dou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongqin","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-1441-9841","authenticated-orcid":false,"given":"Ling","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,15]]},"reference":[{"key":"60797_CR1","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1016\/S0140-6736(25)00261-2","volume":"405","author":"TF Stoop","year":"2025","unstructured":"Stoop, T. F. et al. Pancreatic cancer. Lancet 405, 1182\u20131202 (2025).","journal-title":"Lancet"},{"key":"60797_CR2","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.3390\/jcm14041129","volume":"14","author":"U Hayat","year":"2025","unstructured":"Hayat, U. et al. Current and emerging treatment options for pancreatic cancer: a comprehensive review. J. Clin. Med. 14, 1129 (2025).","journal-title":"J. Clin. Med."},{"key":"60797_CR3","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1001\/jama.2024.16332","volume":"332","author":"G Perrotta","year":"2024","unstructured":"Perrotta, G. et al. Accuracy of clinical staging in early-stage pancreatic ductal adenocarcinoma. JAMA 332, 1108\u20131110 (2024).","journal-title":"JAMA"},{"key":"60797_CR4","unstructured":"AJCC Cancer Staging Manual. (Springer, New York, NY, 2010)."},{"key":"60797_CR5","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1053\/j.semdp.2012.08.010","volume":"29","author":"NV Adsay","year":"2012","unstructured":"Adsay, N. V. et al. Pathologic staging of pancreatic, ampullary, biliary, and gallbladder cancers: Pitfalls and practical limitations of the current AJCC\/UICC TNM staging system and opportunities for improvement. Semin. Diagn. Pathol. 29, 127\u2013141 (2012).","journal-title":"Semin. Diagn. Pathol."},{"key":"60797_CR6","doi-asserted-by":"crossref","unstructured":"Saka, B. et al. Pancreatic ductal adenocarcinoma is spread to the peripancreatic soft tissue in the majority of resected cases, rendering the AJCC T-stage protocol (7th edition) inapplicable and insignificant: a size-based staging system\u00a0(pT1: \u22642, pT2: >2-\u22644, pT3: >4 cm) is more valid and clinically relevant. Ann. Surg. Oncol. 23, 2010\u20132018 (2016).","DOI":"10.1245\/s10434-016-5093-7"},{"key":"60797_CR7","unstructured":"AJCC Cancer Staging Manual. (Springer, New York, NY, 2017)."},{"key":"60797_CR8","doi-asserted-by":"publisher","first-page":"111715","DOI":"10.1016\/j.ejrad.2024.111715","volume":"181","author":"H. J. Jang","year":"2024","unstructured":"Ji Jang, H. et al. Prognostic implication of extra-pancreatic organ invasion in resectable pancreas ductal adenocarcinoma in the pancreas tail. Eur. J. Radiol. 181, 111715 (2024).","journal-title":"Eur. J. Radiol."},{"key":"60797_CR9","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1093\/bjs\/znad146","volume":"110","author":"L Maggino","year":"2023","unstructured":"Maggino, L. et al. Pathological staging in postneoadjuvant pancreatectomy for pancreatic cancer: Implications for adjuvant therapy. Br. J. Surg. 110, 973\u2013982 (2023).","journal-title":"Br. J. Surg."},{"key":"60797_CR10","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1002\/jhbp.1316","volume":"30","author":"W Kwon","year":"2023","unstructured":"Kwon, W. et al. Features of T1 pancreatic cancer and validation of the eighth edition AJCC staging system definition using a Korean-Japanese joint cohort and the SEER database. J. Hepato-Biliary-Pancreat. Sci. 30, 1129\u20131140 (2023).","journal-title":"J. Hepato-Biliary-Pancreat. Sci."},{"key":"60797_CR11","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1016\/j.hpb.2023.06.015","volume":"25","author":"A Hayasaki","year":"2023","unstructured":"Hayasaki, A. et al. Extrapancreatic extension is a better adverse prognostic factor than tumor size in patients with localized pancreatic ductal adenocarcinoma treated with chemoradiotherapy - Comparison of T category between the American Joint Committee on Cancer and Japan Pancreas Society. HPB 25, 1268\u20131277 (2023).","journal-title":"HPB"},{"key":"60797_CR12","doi-asserted-by":"publisher","first-page":"6752","DOI":"10.3748\/wjg.v25.i46.6752","volume":"25","author":"H-Y Chen","year":"2019","unstructured":"Chen, H.-Y., Wang, X., Zhang, H., Liu, X.-B. & Tan, C.-L. Mesenterico-portal vein invasion should be an important factor in TNM staging for pancreatic ductal adenocarcinoma: Proposed modification of the 8th edition of the American Joint Committee on Cancer staging system. World J. Gastroenterol. 25, 6752\u20136766 (2019).","journal-title":"World J. Gastroenterol."},{"key":"60797_CR13","doi-asserted-by":"publisher","first-page":"2484","DOI":"10.1007\/s11605-023-05850-2","volume":"27","author":"M Lee","year":"2023","unstructured":"Lee, M. et al. Reconsidering the absence of extrapancreatic extension in T staging for pancreatic adenocarcinoma in the AJCC (8th ed) Staging Manual using the National Cancer Database. J. Gastrointest. Surg. 27, 2484\u20132492 (2023).","journal-title":"J. Gastrointest. Surg."},{"key":"60797_CR14","doi-asserted-by":"publisher","first-page":"2341","DOI":"10.1016\/j.humpath.2014.06.030","volume":"45","author":"H Park","year":"2014","unstructured":"Park, H. et al. Survival effect of tumor size and extrapancreatic extension in surgically resected pancreatic cancer: Proposal for improved T classification. Hum. Pathol. 45, 2341\u20132346 (2014).","journal-title":"Hum. Pathol."},{"key":"60797_CR15","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1093\/annonc\/mdv500","volume":"27","author":"KS Tewari","year":"2016","unstructured":"Tewari, K. S., Java, J. J., Eskander, R. N., Monk, B. J. & Burger, R. A. Early initiation of chemotherapy following complete resection of advanced ovarian cancer associated with improved survival: NRG oncology\/gynecologic oncology group study. Ann. Oncol. 27, 114\u2013121 (2016).","journal-title":"Ann. Oncol."},{"key":"60797_CR16","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1093\/oxfordjournals.aje.a008670","volume":"143","author":"FJ Nieto","year":"1996","unstructured":"Nieto, F. J. & Coresh, J. Adjusting survival curves for confounders: A review and a new method. Am. J. Epidemiol. 143, 1059\u20131068 (1996).","journal-title":"Am. J. Epidemiol."},{"key":"60797_CR17","doi-asserted-by":"publisher","first-page":"120","DOI":"10.21037\/atm.2018.01.36","volume":"6","author":"Z Zhang","year":"2018","unstructured":"Zhang, Z. et al. Estimate risk difference and number needed to treat in survival analysis. Ann. Transl. Med. 6, 120 (2018).","journal-title":"Ann. Transl. Med."},{"key":"60797_CR18","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1016\/j.jclinepi.2014.03.006","volume":"67","author":"M Coory","year":"2014","unstructured":"Coory, M., Lamb, K. E. & Sorich, M. Risk-difference curves can be used to communicate time-dependent effects of adjuvant therapies for early stage cancer. J. Clin. Epidemiol. 67, 966\u2013972 (2014).","journal-title":"J. Clin. Epidemiol."},{"key":"60797_CR19","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1089\/thy.2023.0561","volume":"34","author":"S Liu","year":"2024","unstructured":"Liu, S. et al. Vitamin E intake and prevalence rates of thyroid dysfunction and autoimmune thyroiditis: A cross-sectional analysis of NHANES data. Thyroid 34, 753\u2013763 (2024).","journal-title":"Thyroid"},{"key":"60797_CR20","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.jacc.2021.05.047","volume":"78","author":"S Kwak","year":"2021","unstructured":"Kwak, S. et al. Markers of myocardial damage predict mortality in patients with aortic stenosis. J. Am. Coll. Cardiol. 78, 545\u2013558 (2021).","journal-title":"J. Am. Coll. Cardiol."},{"key":"60797_CR21","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1097\/JS9.0000000000000844","volume":"110","author":"C Ning","year":"2024","unstructured":"Ning, C. et al. Prediction of survival in patients with infected pancreatic necrosis: a prospective cohort study. Int. J. Surg. Lond. Engl. 110, 777\u2013787 (2024).","journal-title":"Int. J. Surg. Lond. Engl."},{"key":"60797_CR22","doi-asserted-by":"publisher","first-page":"8041","DOI":"10.1038\/s41467-023-43064-x","volume":"14","author":"C Ding","year":"2023","unstructured":"Ding, C. et al. Binge-pattern alcohol consumption and genetic risk as determinants of alcohol-related liver disease. Nat. Commun. 14, 8041 (2023).","journal-title":"Nat. Commun."},{"key":"60797_CR23","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1093\/ije\/dyr218","volume":"41","author":"MJ Knol","year":"2012","unstructured":"Knol, M. J. & VanderWeele, T. J. Recommendations for presenting analyses of effect modification and interaction. Int. J. Epidemiol. 41, 514\u2013520 (2012).","journal-title":"Int. J. Epidemiol."},{"key":"60797_CR24","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1097\/00001648-199209000-00012","volume":"3","author":"DW Hosmer","year":"1992","unstructured":"Hosmer, D. W. & Lemeshow, S. Confidence interval estimation of interaction. Epidemiol. Camb. Mass 3, 452\u2013456 (1992).","journal-title":"Epidemiol. Camb. Mass"},{"key":"60797_CR25","doi-asserted-by":"crossref","unstructured":"Kang, H. et al. Evaluation of the 8th edition AJCC staging system for the clinical staging of pancreatic cancer. Cancers 14, 4672 (2022).","DOI":"10.3390\/cancers14194672"},{"key":"60797_CR26","doi-asserted-by":"publisher","first-page":"4168","DOI":"10.1007\/s00261-025-04831-0","volume":"50","author":"RR Ryu","year":"2025","unstructured":"Ryu, R. R., Kim, J. H., Park, J. & Hwang, S. Small pancreatic ductal adenocarcinoma (\u2264 2 cm): different imaging and clinicopathologic features according to extrapancreatic extension. Abdom. Radiol. N. Y. 50, 4168\u20134180 (2025).","journal-title":"Abdom. Radiol. N. Y."},{"key":"60797_CR27","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1038\/s41591-024-03362-3","volume":"31","author":"AM Varghese","year":"2025","unstructured":"Varghese, A. M. et al. Clinicogenomic landscape of pancreatic adenocarcinoma identifies KRAS mutant dosage as prognostic of overall survival. Nat. Med. 31, 466\u2013477 (2025).","journal-title":"Nat. Med."},{"key":"60797_CR28","doi-asserted-by":"publisher","first-page":"189220","DOI":"10.1016\/j.bbcan.2024.189220","volume":"1879","author":"H Yao","year":"2024","unstructured":"Yao, H. et al. New insight into the role of SMAD4 mutation\/deficiency in the prognosis and therapeutic resistance of pancreatic ductal adenocarcinomas. Biochim. Biophys. Acta Rev. Cancer 1879, 189220 (2024).","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"60797_CR29","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1158\/0008-5472.CAN-24-2330","volume":"85","author":"EG Lloyd","year":"2025","unstructured":"Lloyd, E. G. et al. SMAD4 and KRAS status shapes cancer cell-stromal cross-talk and therapeutic response in pancreatic cancer. Cancer Res. 85, 1368\u20131389 (2025).","journal-title":"Cancer Res."},{"key":"60797_CR30","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1200\/JCO.21.02233","volume":"40","author":"E Versteijne","year":"2022","unstructured":"Versteijne, E. et al. Neoadjuvant chemoradiotherapy versus upfront surgery for resectable and borderline resectable pancreatic cancer: Long-term results of the dutch randomized PREOPANC trial. J. Clin. Oncol. 40, 1220\u20131230 (2022).","journal-title":"J. Clin. Oncol."},{"key":"60797_CR31","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/S2468-1253(22)00348-X","volume":"8","author":"P Ghaneh","year":"2023","unstructured":"Ghaneh, P. et al. Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trial. Lancet Gastroenterol. Hepatol. 8, 157\u2013168 (2023).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"60797_CR32","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.pan.2017.11.011","volume":"18","author":"S Isaji","year":"2018","unstructured":"Isaji, S. et al. International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017. Pancreatology 18, 2\u201311 (2018).","journal-title":"Pancreatology"},{"key":"60797_CR33","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/s41379-020-00683-9","volume":"34","author":"BV Janssen","year":"2021","unstructured":"Janssen, B. V. et al. Amsterdam international consensus meeting: Tumor response scoring in the pathology assessment of resected pancreatic cancer after neoadjuvant therapy. Mod. Pathol. 34, 4\u201312 (2021).","journal-title":"Mod. Pathol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-60797-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-60797-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-60797-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T10:16:49Z","timestamp":1789467409000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-60797-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,15]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["60797"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-60797-z","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,15]]},"assertion":[{"value":"12 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Since the SEER database is publicly available, this study was exempt from review by the Ethics Committee of the authors\u2019 hospital.","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent was waived due to the use of de-identified data from the SEER public database.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"28716"}}